Overview

Clofarabine Pre-conditioning Followed by Stem Cell Transplant for Non-remission AML

Status:
Recruiting
Trial end date:
2026-06-03
Target enrollment:
Participant gender:
Summary
The Investigators would like to study the incidence of complete remission (CR) at day +30 after Clofarabine followed by haploidentical transplant. The conditioning regimen used is Fludarabine, Busulfan (2 doses) or cyclophosphamide (2 doses) and Total Body Irradiation (TBI) with post transplant cyclophosphamide for patients with Acute Myeloid Leukemia (AML) who are not in remission prior to considering allogeneic transplant with haploidentical donors.
Phase:
Phase 2
Details
Lead Sponsor:
Milton S. Hershey Medical Center
Treatments:
Busulfan
Clofarabine
Cyclophosphamide
Fludarabine
Fludarabine phosphate
Lenograstim
Mycophenolic Acid
Sargramostim
Tacrolimus
Vidarabine